Registry for patients with hairy cell leukemia
Official title: Clinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia
Run by Ohio State University Comprehensive Cancer Center · NCT02560883 · Data updated 2026-11-12
This study is collecting information from people with hairy cell leukemia to help find better treatments and improve their quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Locations | 8 sites (Miami, Florida and 7 other locations) |
| Status | Recruiting |
| Started | January 2, 2013 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | July 2, 2026 |
| Trial ID | NCT02560883 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this registry are adults diagnosed with classic or variant hairy cell leukemia.
✕Probably not a fit
Children and individuals without a diagnosis of hairy cell leukemia will not benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This registry aims to collect and centralize de-identified data from patients diagnosed with hairy cell leukemia to facilitate research and improve patient outcomes. By gathering information on symptoms, treatment complications, and disease progression, the registry will help identify effective treatments and potential new therapies. Collaborating with multiple institutions, the study emphasizes safeguarding patient confidentiality while enabling comprehensive data analysis. The ultimate goal is to enhance the quality of life for patients living with this rare form of leukemia.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment strategies and better management of hairy cell leukemia.
How similar studies have gone: Other registries for rare diseases have shown success in improving patient outcomes and guiding research, indicating a promising approach for this study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion: * Patients with classic hairy cell leukemia * Patients with the variant of hairy cell leukemia. Exclusion: * Children are excluded from the study, since Hairy Cell Leukemia wasn't described in children.
Where it's running
-
University of Miami/Soffer Clinical Research Center
Miami, Florida, United States Recruiting -
Mount Sinai Medical Center of Florida
Miami Beach, Florida, United States Recruiting -
Mayo Clinic
Rochester, Minnesota, United States Recruiting -
University of Rochester /Wilmot Cancer Institute
Rochester, New York, United States Recruiting -
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States Recruiting -
Peter MacCallum Cancer Center
Melbourne, Victoria, Australia Recruiting
Show 2 more locations
-
BC Cancer, Part of the Provincial Health Services Authority
Vancouver, Britsh Columbia, Canada Recruiting -
Cancer Care Manitoba
Winnipeg, Manitoba, Canada Recruiting
Study contacts
- Principal investigator: Michael Grever, MD — The Ohio State University Comprehensive Cancer Center
- Study coordinator: Hairy Cell Leukemia Research Data Registry
- Email: HCLRegistry@osumc.edu
- Phone: 614-685-4296
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Examining factors that affect the effectiveness of post-transplant cyclophosphamide
This study is trying to see how genetic factors and drug levels affect the success of a treatment called post-transplant cyclophosphamide in patients who have had a stem cell transplant.
-
Multiomic analysis in relapsed small-cell lung cancer with DLL3 T cell engager
This observational study tests how blood and tumor markers change over time in adults with relapsed small-cell lung cancer who are receiving a DLL3-targeted therapy, to see if those changes relate to clinical outcomes.
-
Alternating chemo-immunotherapy and FGFR inhibitor for FGFR-positive biliary tract cancer
This phase 2 trial tests whether alternating gemcitabine/cisplatin with durvalumab and the FGFR2 inhibitor pemigatinib can help people with unresectable or metastatic biliary tract cancers that have FGFR alterations.
-
Venetoclax plus Zanubrutinib for CLL/SLL in frontline or previously treated patients
This phase II trial tests if venetoclax plus zanubrutinib can safely and effectively treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma, including those who are newly diagnosed and those who have had prior therapy.
-
DCE-MRI to help plan surgery for borderline resectable pancreatic cancer
This trial tests whether adding DCE-MRI imaging to standard care can better gauge how pancreatic tumors respond to treatment in patients whose cancer might be removable by surgery.
-
Navigation program to boost survivorship support participation for non-metastatic breast cancer survivors
This program tests whether a patient navigation service helps non-metastatic breast cancer survivors use survivorship support services more often.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.